Bisimide compounds

A method for treating a living body afflicted with a cancer selected from the group consisting of lung, colon, and epidermoid carcinoma comprising the step of administering to the living body an amount of a compound selected from those of formula (I):

• ##STR18## in which:
• X and Y, which may be identical or different, represent hydrogen or halogen or linear or branched (C.sub.1 -C.sub.6) alkyl, linear or branched (C.sub.1 -C.sub.6) trihaloalkyl, linear or branched (C.sub.1 -C.sub.6) alkoxy, hydroxyl, cyano nitro, amino, alkylamino, or dialkylamino,
• Z represents a linear or branched C.sub.4 to C.sub.12 alkylene chain in which one or more --CH.sub.2 -- groups are optionally replaced by any one of the following atoms or groups:
• --NR-- (in which R represents hydrogen or linear or branched (C.sub.1 -C.sub.6) alkyl), --O--, --S--, --SO--, --SO.sub.2 --, or --CONH--,
• A forms, with two adjacent carbon atoms of the phenyl ring:
• a substituted or unsubstituted phenyl ring,
• a substituted or unsubstituted naphthyl ring, or
• a substituted or unsubstituted tetrahydronaphthyl ring or substituted or unsubstituted 1,4-dioxo-1,2,3,4-tetrahydronaphthyl ring, ##STR19## represents the following group:
• ##STR20## in which:
• X.sub.1 and Y.sub.1, which may be identical or different, represent hydrogen or halogen or linear or branched (C.sub.1 -C.sub.6) alkyl, linear or branched (C.sub.1 -C.sub.6) trihaloalkyl, linear or branched (C.sub.1 -C.sub.6) alkoxy, hydroxyl, cyano, nitro, amino, alkylamino, or dialkylamino,
• A.sub.1 forms, with two adjacent carbon atoms of the phenyl ring:
• a substituted or unsubstituted phenyl ring,
• a substituted or unsubstituted naphthyl ring, or
• a substituted or unsubstituted tetrahydronaphthyl ring or substituted or unsubstituted 1,4-dioxo-1,2,3,4-tetrahydronaphthyl ring,
• its optical isomers and its addition salts with a pharmaceutically-acceptable acid or base, which is effective for amelioration thereof.

A pharmaceutical composition comprising as active principle an effective amount of a compound selected from those of formula (I):

• ##STR22## in which:
• X and Y, which may be identical or different, represent hydrogen or halogen or linear or branched (C.sub.1 -C.sub.6) alkyl, linear or branched (C.sub.1 -C.sub.6) trihaloalkyl, linear or branched (C.sub.1 -C.sub.6) alkoxy, hydroxyl, cyano, nitro, amino, alkylamino, or dialkylamino,
• Z represents a linear or branched C.sub.4 to C.sub.12 alkylene chain in which one or more --CH.sub.2 -- groups are optionally replaced by any one of the following atoms or groups;
• --NR-- (in which R represents hydrogen or linear or branched (C.sub.1 -C.sub.6) alkyl), --O--, --S--, --SO--, --SO.sub.2 --, or --CONH--,
• A forms, with two adjacent carbon atoms of the phenyl ring:
• a substituted or unsubstituted phenyl ring,
• a substituted or unsubstituted naphthyl ring, or
• a substituted or unsubstituted tetrahydronaphthyl ring or substituted or unsubstituted 1,4-dioxo-1,2,3,4-tetrahydronaphthyl ring, ##STR23## represents the following group:
• ##STR24## in which:
• X.sub.1 and Y.sub.1, which may be identical or different, represent hydrogen or halogen or linear or branched (C.sub.1 -C.sub.6) alkyl, linear or branched (C.sub.1 -C.sub.6) trihaloalkyl, linear or branched (C.sub.1 -C.sub.6) alkoxy, hydroxyl, cyano, nitro, amino, alkylamino, or dialkylamino,
• A.sub.1 forms, with two adjacent carbon atoms of the phenyl ring:
• a substituted or unsubstituted phenyl ring,
• a substituted or unsubstituted naphthyl ring, or
• a substituted or unsubstituted tetrahydronaphthyl ring or substituted or unsubstituted 1,4-dioxo-1,2,3,4-tetrahydronaphthyl ring,
• together with one or more pharmaceutically-acceptable excipients or vehicles.